Human Microbiome Market would Expand at a Healthy CAGR of 9.80% Between 2018 and 2026


Posted April 10, 2019 by hawerr

Human microbiome diagnostics market is projected to expand at a robust CAGR of 9.8% during the forecast period

 
The human microbiome market exhibits significant potential in the near future due to huge untapped medical needs. The market is set to create lucrative opportunities due to a large number of ongoing clinical trials and entry of new players in the market. Presently, the human microbiome market is in the nascent stage, and therapies are still in the pre-clinical and clinical stage. Diagnostics is also in the development phase of the product life cycle. In November 2016, uBiome launched the SmartGut test for diagnosis of gut health disorders. Companies have begun to allocate significant funds for research and development and management of clinical studies for innovative therapies. Lack of targeted drugs in the market for specific conditions, such as C.difficile infection and ulcerative colitis, makes it a highly opportune condition for players to set their innovative drug ideas on the path of commercial success. The human microbiome comprises genetic material within a microbiota (the entire collection of microorganisms, such as bacteria, virus, fungi, archea, etc. in specific areas of the human body, such as the gut, vagina, oral cavity, etc.). The human microbiome market is driven by factors, such as rise in clinical trials for gut health-based diseases and increase in funds by investors or venture capital firms/individual venture capitalists for research and development on human microbiome-based therapies. However, the present lack of certainty in the performance of these drugs in the long-run and regulatory hurdles are anticipated to restrain the growth of the market during the forecast period. Nevertheless, the human microbiome diagnostics market is anticipated to be driven by rising preference of patients for descriptive, rapid, and non-invasive sequencing-based microbiome tests for diseases such as colon cancer, vaginosis, and Crohn’s disease.

Report Overview: https://www.transparencymarketresearch.com/human-microbiome-market.html

The global human microbiome diagnostics market is projected to expand at a robust CAGR of 9.8% during the forecast period, i.e. between 2018 and 2026, while the human microbiome therapeutics market is likely show similar exceptional growth with a CAGR of 9.6% during the forecast period from 2020 to 2026. Driven by huge unmet clinical needs for disease management and rising research and development expenditure; the global human microbiome diagnostics market is anticipated to be valued at US$ 892.1 Mn in 2018. It is expected to reach a value of US$ 1,888.9 Mn by 2026, reflecting a CAGR of 9.8%, while the global human microbiome therapeutics market is anticipated to be valued at US$ 1,245.3 Mn in 2020. It is expected to reach a value of US$ 2,160.9 Mn by 2026, registering a CAGR of 9.6%.

Based on therapeutic area, the human microbiome therapeutics market has been segmented into gastrointestinal disorders, metabolic disorders, women’s health, skin disorders, and others. The others segment includes therapeutic areas for infant health, infections and autoimmune diseases, and rare diseases. The gastrointestinal disorders segment is likely to capture the leading position in the market and exhibit high attractiveness due to the presence of a large number of therapies under clinical trials directed toward treating gastrointestinal disturbances, coupled with the existing unmet medical needs in gut health concerns. According to the CDC, on the basis of a study conducted in 2015, in the U.S., approximately 1 out of every 11 patients, over 65 years of age with C. difficile, dies within 30 days of diagnosis, which is an alarming figure. The CDC also estimated that about one of five patients had a recurrence of the illness. Thus, therapies such as SER-109, targeted toward the prevention of recurrent clostridium difficile infection (CDI) has shown promising results in clinical trials with less reoccurrence rate. This provides lucrative opportunities during the forecast period. The gastrointestinal diseases segment is likely to capture over 59.7% of the global human microbiome therapeutics market in 2020.

The global human microbiome diagnostics market has been segmented on the basis of indication, technology, and region. The gastrointestinal and metabolic disorders segments are projected to exhibit a total incremental opportunity of US$ 586.9 Mn from 2018 to 2026. Launch of tests aimed at diagnosing gut health imbalances and disorders, such as SmartGut by uBiome, is likely to propel the segment during the forecast period.

Obtain the Sample Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3999

Key companies profiled in the report include AOBiome LLC, Osel, Inc., Seres Therapeutics, Second Genome, uBiome, Inc., Metabiomics Corp., Rebiotix, Inc., Vedanta Biosciences, Enterome, Biosciences, and Synthetic Biologics, Inc.

About Us:

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: https://www.transparencymarketresearch.com
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Transparency Market Research
Country United States
Categories Health , Medical , News
Tags Human Microbiome Market
Last Updated April 10, 2019